How BioVaxys Technology Corp. (CSE:BIOV) (OTC:BVAXF) (FR:5LB) Swooped in to Acquire a Promising Biotech Asset with Multi-Billion-Dollar Potential and Over $300M in R&D Already Spent on it for Less Than a Million Dollars.

Imagine finding a hidden treasure in an old attic, a painting thought to be worth a little but actually a masterpiece worth millions. This happened in real life with a painting by Rembrandt, a famous artist, which was first thought to be worth $15,000, only to be sold for almost $14 million—a 93x return!^[1]

This story is like a hint for smart investors: sometimes, what looks ordinary at first can turn out to be incredibly valuable.

Just like treasure hunters, some smart companies look for hidden gems in businesses that are having a tough time, where they can find what are known as ‘distressed assets’.

They seek to find something special that everyone else missed, buy it for a steep discount, and then repackage or rejuvenate it, turning it into something amazing that makes a huge profit.

You’ve probably already heard of some of these, but didn’t know how successful they actually turned out to be. Here are some more prominent examples:

• Converse – Back in 2003, the historically significant shoemakers filed for bankruptcy, only for shoe giant Nike to swoop in and pay $305 million^[2] to resurrect the brand. Nike has made billions in revenue from Converse over the years since, earning +$2.4 billion from the brand in 2023 alone^[3].
• Hostess – In 2012, the Twinkies baker announced it was liquidating its assets after a labor dispute. By July 2013, astute businessman Daren Metropoulos and his group pursued and acquired Hostess for $410 million^[4] en route to the “sweetest comeback in the history of ever”^[5]. Within just two years, the business was rehabilitated and produced a $2 billion gain^[6]. By late 2023, the enterprise was sold again for ~$5.6 billion^[7].
• Marvel – In 1996, the comic book titan filed for bankruptcy, which sparked a billionaire vs billionaire feud between Ronald Perelman and Carl Icahn, only for action-figure company Toy Biz to swoop in and save the brand, paying $280 million^[8]. This masterstroke would go on to attract a sale to Disney for $4 billion in 2009^[9]. And of course, Disney would go on to make more than $30 billion in global box office off of movies alone^[10].

But in each of these cases, the buyers each still had to put up hundreds of millions of dollars for these valuable assets, to turn them into multi-billion-dollar assets.

What if someone were to find an asset with multi-billion-dollar potential, and snap it up for less than $1 million, and get it over the finish line?

One such example is happening RIGHT NOW in the biotech sector, with all the makings of what could become the BIGGEST asset-rescue deal in the industry’s history.

Enter BioVaxys Technology Corp. (CSE:BIOV) (OTC:BVAXF) (FR:5LB), a junior biotech company that just pulled off a masterful acquisition of a technology platform called DPX™, that has already had over $300M of R&D invested into it, and could potentially become worth billions.

Savvy biotech firm BioVaxys made a move that could change lives and reward investors. They saw a chance with DPX™, a medical tech with huge potential.

While the original creators, despite a strong start, nearly reaching a billion-dollar market cap, and spending hundreds of millions on R&D, didn’t succeed, BioVaxys saw a diamond in the rough.

They didn’t just buy the tech; they got all the research and patents too. Now, BioVaxys is ready to finish what was started, to make DPX™ a name in health care. This deal is more than a purchase—it’s a step toward new treatments for people everywhere.

This move by BioVaxys is big news for anyone looking for smart investment chances. They’ve got a plan to make DPX™ shine, bringing new hope to medicine and possibly big returns for those who see the promise in their bold step.

Top 10 Reasons Why Investors Should Pay Close Attention to BioVaxys Technology Corp. (CSE:BIOV) (OTC:BVAXF) (FR:5LB) :

1. Strategic Cost-Efficient Acquisition: At a cost well below its developmental value, BioVaxys acquired DPX™, a technology platform with significant prior investment in research and development, showcasing the company’s ability to identify and capitalize on strategic opportunities.
2. Significant R&D Foundation: Over $300M has already been spent on developing DPX™, meaning BioVaxys is building upon a substantial foundation of research.
3. Potential for Breakthrough: Based on solid scientific research and supporting clinical data, DPX™ has the potential to revolutionize cancer treatment and vaccine development, representing a breakthrough in medical technology.
4. Unmet Medical Needs: With a focus on conditions that currently have few effective treatments, BioVaxys is targeting a critical gap in the healthcare market.
5. Market Opportunity: The fields of cancer treatment and vaccine development are high-value markets with growing demand, suggesting a significant opportunity for BioVaxys.
6. Expertise and Vision: The acquisition demonstrates BioVaxys’s expertise and vision in recognizing undervalued assets with potential.
7. Public Health Impact: If successful, DPX™ could have a global impact on health care, positioning BioVaxys as a leader in the biotech sector against cancer, allergies, and infectious diseases.
8. Patent Portfolio: The deal includes a substantial patent library, which could offer competitive advantages and opportunities for additional revenue streams through licensing.
9. Revitalizing Potential: BioVaxys aims to revitalize and advance DPX™, indicating a commitment to innovation and value creation.
10. Potential Partnerships: BioVaxys’s DPX™ platform could attract partnership opportunities with larger pharmaceutical companies, which can offer additional expertise and resources.

Discover DPX™: The Next Frontier in Immunotherapy

DPX™ stands out in today’s medical world. It’s a special kind of technology that teaches the body to fight cancer and disease, and presents a big chance to help people.

BioVaxys sees how great DPX™ can be. They’re ready to bring it back, like a phoenix rising up. They’re not starting over—there’s already over $300 million of research behind DPX™.

DPX™ is unique because it’s made to train the immune system very carefully. It goes after the real problems causing the disease, not just the symptoms. It could make people’s health better for a long time.

Everyone should now be looking very seriously at BioVaxys, as it begins to breathe new life into DPX™. People who invest money, doctors, and patients want to see what DPX™ can  do. With BioVaxys leading, DPX™’s journey is about new starts, big chances, and changing how we treat tough diseases.

Seemingly Endless Possibilities

The DPX™ platform, with its robust and flexible design, could revolutionize future vaccine and therapeutic developments beyond its current applications. Envisioned as a versatile carrier, it has the potential to deliver not only proteins and peptides, but also mRNA, opening avenues for rapid response to emerging infectious diseases.

Furthermore, its adaptability could extend to treatments for chronic immune system conditions, allergies, and autoimmune diseases, harnessing the body’s immune system in precise, targeted ways. This broad potential positions DPX™ as a key player in the next generation of immunotherapies, offering hope for more effective, personalized medical solutions.

Before its transition, IMV engaged in several clinical studies leveraging the DPX™ platform, aiming to address a range of health issues, from cancer treatments to infectious diseases, showcasing the platform’s versatility and potential in immunotherapy. These studies were pivotal in demonstrating DPX™’s efficacy and safety across various medical applications.

List of IMV’s Clinical Studies:

• DPX™-Survivac™: Targeting ovarian and other cancers
• DPX™-RSV: Focused on Respiratory Syncytial Virus
• DPX™-COVID-19: Vaccine candidate against COVID-19
• Collaborative studies in infectious diseases with renowned institutions

This snapshot (captured from an archive of the IMV website^[11]) highlights DPX™’s journey through clinical trials, underscoring its broad applicability in advancing medical science.

Case Study: Lipid Nanoparticle (LNP) Delivery

 In a world where breakthroughs can redefine the future, Acuitas Therapeutics emerged as an unsung hero in the fight against COVID-19^[12]. Specializing in lipid nanoparticle (LNP) delivery systems, Acuitas played a critical role in the success of mRNA vaccines.

Their technology enabled the safe and effective transport of mRNA into cells, marking a pivotal moment in vaccine development and distribution.

The lipid nanoparticle (LNP) delivery technology, crucial for the success of mRNA vaccines, particularly in the fight against COVID-19, has connections to both Acuitas Therapeutics and Arbutus Biopharma. This situation stems from a complex background of development and licensing agreements in the biotech industry.

Arbutus Biopharma originally developed a range of LNP technologies, which have been instrumental in advancing RNA-based therapies. Acuitas Therapeutics, on the other hand, specializes in the development and application of these LNP delivery systems for mRNA vaccines and therapeutics. There has been some contention and legal disputes between Acuitas and Arbutus over the rights to use certain LNP technologies, especially in the context of COVID-19 vaccines^[13].

Acuitas went on to partner with majors such as Pfizer^[14] showcasing the power of collaboration, marrying innovative technology with pharmaceutical expertise to deliver a global solution in record time. This strategic alliance not only accelerated the vaccine’s arrival but also spotlighted Acuitas’s technology, setting a new standard in therapeutic delivery.

Now, imagine a similar story unfolding with BioVaxys. With its DPX™ platform, BioVaxys holds the keys to a new realm of possibilities in immunotherapy and vaccine development. Like Acuitas, BioVaxys has the potential to revolutionize healthcare through strategic partnerships and innovation. The DPX™ platform, with its unique delivery mechanism, could become as integral to future treatments as LNP technology has been to mRNA vaccines.

As we look to the future, BioVaxys’s journey could mirror that of Acuitas, transforming the DPX™ platform into a cornerstone of medical innovation. With the right collaborations and continued investment in research, BioVaxys stands on the brink of writing its own success story, potentially surpassing the achievements of Acuitas by broadening the scope of diseases targeted and improving the efficacy of treatments. The story of Acuitas serves not just as inspiration but as a blueprint for what BioVaxys could achieve, highlighting the boundless potential of merging pioneering technology with visionary strategy.

Quick Recap: Why BioVaxys Technology Corp. (CSE:BIOV) (OTC:BVAXF) (FR:5LB) Should Be On Your Radar:

1. Smart Buy: BioVaxys secured DPX™ for much less than its research value, showing their knack for spotting and seizing smart opportunities.
2. Established Research: BioVaxys builds on the extensive $300M+ research groundwork already laid for DPX™.
3. Innovation Potential: DPX™ stands on the brink of changing cancer and vaccine science based on robust research.
4. Healthcare Gap: BioVaxys targets crucial healthcare needs that are currently underserved.
5. Lucrative Markets: The company enters the high-value arenas of cancer and vaccine markets, poised for growth.
6. Strategic Insight: The acquisition underscores BioVaxys’s strategic acumen in identifying high-potential assets.
7. Health Impact: Success with DPX™ could place BioVaxys at the forefront of global healthcare solutions.
8. Patent Strength: A strong patent collection from the deal may provide a competitive edge and new revenue paths.
9. Renewed Momentum: BioVaxys is set to propel DPX™ forward, emphasizing their commitment to unlocking hidden value.
10. Collaborative Prospects: The DPX™ platform’s potential may draw collaborations with pharma giants, bringing in more expertise and capital.

BEFORE YOU GO!

BioVaxys Technology Corp. (CSE:BIOV) (OTC:BVAXF) (FR:5LB) isn’t just another player in the biotech sector; it’s a pioneer poised to redefine the future of immunotherapy and vaccine development. With its innovative Haptenix© platform behind development of ovarian cancer vaccine candidate BVX-0918, and the addition of

DPX™ platform technology, BioVaxys stands at the forefront of addressing some of the most pressing medical challenges of our time, including cancer, allergies and infectious diseases like COVID-19 and RSV.

The company’s approach, leveraging the power of the immune system through targeted delivery mechanisms, is not only ground breaking but also offers the potential for scalable and effective solutions. As the world continues to grapple with health crises, the work of BioVaxys could prove instrumental in shaping the next generation of medical treatments.

Stay informed about all the latest advancements and updates from BioVaxys Technology Corp. by clicking here.

USA News Group
Editorial Staff 

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for BioVaxys Technology Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BioVaxys Technology Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BioVaxys Technology Corp. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares BioVaxys Technology Corp. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of BioVaxys Technology Corp. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

^[1] https://www.cnn.com/style/rembrandt-auction-adoration-kings-sothebys-gbr-scli-intl

^[2] https://www.wsj.com/articles/SB105778918424757500

^[3] https://www.statista.com/statistics/241850/sales-of-nikes-non-nike-brands-2006-2010/

^[4] https://www.prnewswire.com/news-releases/hostess-brands-selects-apollo-global-management-and-metropoulos–co-as-winning-bidder-for-majority-of-snack-cake-business-including-twinkiesr-197536231.html

^[5] https://www.bakingbusiness.com/articles/60082-hostess-saga-truly-the-sweetest-comeback-in-the-history-of-ever

^[6] https://www.forbes.com/sites/stevenbertoni/2015/04/15/twinkie-billion-dollar-comeback-hostess-metropoulos-apollo-jhawar/?sh=77d013767235

^[7] https://www.prnewswire.com/news-releases/the-j-m-smucker-co-to-acquire-hostess-brands-to-accelerate-focus-on-convenient-consumer-occasions-301923243.html

^[8] https://money.cnn.com/1998/06/29/companies/marvel/

^[9] https://www.nytimes.com/2009/09/01/business/media/01disney.html

^[10] https://www.cnbc.com/2023/11/14/how-disney-can-save-marvel-cinematic-universe.html

^[11] https://web.archive.org/web/20230207172926/https://www.imv-inc.com/product-pipeline

^[12] https://www.forbes.com/sites/nathanvardi/2021/08/17/covids-forgotten-hero-the-untold-story-of-the-scientist-whose-breakthrough-made-the-vaccines-possible/?sh=3949ee38354f

^[13] https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-settles-litigation-terminating-acuitas-rights-lnp-0

^[14] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-agreement-acuitas-therapeutics-lipid

Early investors in BriaCell Therapeutics Corp. (Nasdaq: BCTX) could see explosive upside potential

Alert: Analyst Places $15 Valuation Target on BCTX Shares

Breaking News

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer – Read More…

BriaCell Therapeutics Receives Buy Rating from Analyst – Read More…

Featured Webcast

Dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.

Dr. William Williams M.D., CEO – Listen Now…

A significant medical breakthrough is sorely needed in the fight against breast cancer.

According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive breast cancer.

And breast cancer deaths are estimated to be more than 43,000 per year – making it the second leading cause of cancer death in women.

But there may be hope on the way in the near future.

One under-the-radar company, whose lead drug candidate was awarded Fast Track status by the FDA, appears to be on the verge of a massive disruption in cancer treatment.

That company is BriaCell Therapeutics Corp. (Nasdaq: BCTX), a clinical stage immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.

And they’re getting impressive results.

BriaCell Therapeutics Corp.’s mission is to develop novel immunotherapies to fight cancer. The company is dedicated to enhancing the lives of women with breast cancer who have limited therapy options.

Immunotherapies use the body’s own immune system to destroy cancer cells while offering the potential for higher levels of safety and efficacy than chemotherapy; and may also prevent cancer recurrence.

The company’s patented immunotherapy treatments have shown extraordinary potential, making it one of the more attractive high-upside biotech stocks for investors to consider in 2023.

6 Key Reasons Why BriaCell Therapeutics Corp. (Nasdaq: BCTX) Appears to Offer Explosive Upside Potential in 2023

Key Reason #1: The company’s lead drug candidate, Bria-IMT™, has shown extraordinary potential to date and is advancing rapidly.

The company’s lead drug candidate, Bria-IMT™, was developed and characterized by a team of dedicated scientists and clinicians as a targeted immunotherapy being developed for the treatment of advanced breast cancer.

Specifically, Bria-IMT™ is targeting advanced metastatic breast cancer – the cause of over 40,000 deaths per year in the U.S.

Bria-IMT™ was awarded Fast Track designation by the FDA. The Fast Track process is designed to, as the FDA puts it, “facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.”

In other words, it’s a way to get important new drugs reviewed and approved much faster…which can mean good news for patients as well as prospective investors.

About Bria-IMT™

• Bria-IMT™ is a genetically engineered human breast cancer cell line with features of immune cells and is clinically used as a targeted immunotherapy.
• Over four dozen patients treated to-date show robust responses to the treatment in selected sub-groups.
• And the Phase I/IIa safety and efficacy study shows similar or superior results to other advanced or approved drugs when they were at a comparable stage.
• Bria-IMT™ is now being tried in Part II of a Phase I/II trial in combination with immune checkpoint inhibitors.

Positive feedback from End of Phase II Meeting with FDA

In January 2023, BriaCell Therapeutics Corp. (Nasdaq: BCTX) announced that it had received agreement and positive feedback from its End of Phase II meeting with the FDA regarding BriaCell’s lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor (under Fast Track designation), in advanced metastatic breast cancer.

BriaCell and the FDA have agreed on the primary end point – linked to patient survival – the essential elements of the study design, and the type of patients to be enrolled in BriaCell’s upcoming pivotal clinical study.

This pivotal registration study will be enrolling advanced metastatic breast cancer patients for whom no approved treatment options exist. Patient dosing should be able to start in the summer of 2023.

Moving directly into a pivotal study shortly after receiving Fast Track status has greatly advanced BriaCell’s lead clinical program timetable with the ultimate goal of commercializing its novel immunotherapy approach for women with no approved treatment options.

Combination regimen with Keytruda® shows positive results

70% of patients show positive results in combination with Incyte’s retifanlimab

One of the more remarkable results seen to date with Bria-IMT™ and retifanlimab showed the efficacy of the treatment in metastasis behind the patient’s eye, with a complete resolution of the tumor.

Key Reason #2: BriaCell’s collaboration agreement with Incyte Corporation (Nasdaq: INCY).

BriaCell Therapeutics Corp. (Nasdaq: BCTX) enjoys a corporate collaboration and supply agreement with Incyte Corporation (Nasdaq: INCY).

Incyte Corporation is a massive, $16 billion market cap biopharmaceutical company with a history of developing – and acquiring – successful treatments and therapies.

BriaCell’s agreement with Incyte is focused on the selection of novel combinations for the treatment of advanced breast cancer along with the ongoing clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s retifanlimab (Zynyz) for advanced breast cancer. Note that Zynyz was recently approved for the treatment of urothelial cancer.

As part of this agreement, BriaCell is evaluating combinations of novel therapeutics for the treatment of patients with advanced breast cancer. Incyte provides BriaCell with Zynyz in the ongoing combination study with Bria-IMT™.

The ongoing randomized Phase II trial of Bria-IMT™ plus Incyte’s retifanlimab has shown impressive results.

Of 12 patients recently tested, 70% showed either disease control or progression-free survival benefits vs. the last therapy used. And “better quality of life” and “less pain” were reported by many gravely ill advanced metastatic breast cancer patients.

This collaboration agreement with Incyte is a tremendous positive for BriaCell not only because of the results being achieved with the combination treatments…but also because this collaboration places BriaCell firmly on the radar of larger companies such as Incyte for future collaboration or potential acquisition.

Key Reason #3: Bria-OTS™ “Off-the-Shelf Personalized” immunotherapy is another of the many impressive treatment candidates in the company’s pipeline.

Recently awarded a patent by the USPTO, BriaCell Therapeutics Corp. (Nasdaq: BCTX) is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for the treatment for advanced stage breast cancer.

Collaborating with the National Cancer Institute (part of NIH), the company believes its cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type.

BriaCell is engineering 15 unique HLA types (molecules) into four Bria-OTS™ cell lines, allowing for matching of over 99% of patients with advanced breast cancer.

This obviously greatly expands the potential market for the treatment, and BriaCell eventually plans to expand the technology behind Bria-OTS™ to different cancer types, with platform potential.

BriaCell expects to file an IND in the first half of 2023, and clinical studies should begin shortly after IND clearance. The company then expects to begin dosing patients with advanced metastatic breast cancer in a Phase I/II clinical trial in 2023.

While BriaCell’s focus to date has primarily been on Bria-IMT™ and Bria-OTS™, the company has a robust pipeline of additional drug candidates including potential treatments for melanoma, lung cancer and prostate cancer among others.

Key Reason #4: The biotech market can offer investors the potential to create outsized fortunes.

The biotech sector is one of the most intriguing areas of the market for profit-seekers, as the potential exists for both small and large companies to skyrocket in value.

Thanks to modern technology and innovation, new ways to treat and prevent diseases are being created that are not only saving lives…but also creating massive profit opportunities.

In 2022 alone, a number of biopharma stocks delivered triple-digit gains, including:

• Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) – this developer of therapeutics for treatment of rare genetic diseases of obesity soared 192% in 2022.

• Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) – this clinical-stage biopharmaceutical company saw its shares skyrocket 243% in 2022. It’s worth highlighting that Madrigal’s Founder and Chief Medical Officer Rebecca Taub, M.D. is on BriaCell’s board of directors.

• And Verona Pharma (Nasdaq: VRNA) – this developer of treatments for respiratory diseases vaulted 289% in 2022!

The potential to make a significant impact on a large population through novel treatments or vaccines is what makes the biotech sector so attractive to investors.

Few sectors can offer such promising prospects for exponential growth and significant returns.

Today, BriaCell Therapeutics Corp. (Nasdaq: BCTX) offers investors one of the best ways to play the biotech market for maximum upside potential.

Key Reason #5: BriaCell appears to be significantly undervalued when compared to its peers.

The potential for rapid growth in valuation is higher in the biotech sector than perhaps any other.

Part of the reason why this potential exists is that often companies – even those with impressive treatments – can fly under Wall Street’s radar for an extended period of time.

In the case of BriaCell Therapeutics Corp. (Nasdaq: BCTX), investors considering the company today are looking at a company with a market capitalization just a fraction of that seen by its closest peers in the biotech space.

Take Allogene Therapeutics, Inc. (Nasdaq: ALLO), for example. Allogene is a clinical stage immuno-oncology company that develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Allogene Therapeutics has a similar number of treatments in its pipeline – with two in Phase II clinical trials – yet has a market cap more than six times greater than BriaCell Therapeutics.

The same goes for other peers, including Fate Therapeutics, Inc. (Nasdaq: FATE) with a market cap roughly five times greater than BriaCell’s…and Sana Biotechnology, Inc. (Nasdaq: SANA) with a market cap six times greater than that of BriaCell.

As BriaCell Therapeutics continues to advance – and show strong results with its trials – it will gain an increasing amount of attention, increasing the likelihood of a surge in valuation and attracting the attention of larger biotech companies looking for potential buyout candidates.

An objective comparison of the company – and its current market cap – to its peers shows that, given the success the company has already demonstrated, BriaCell Therapeutics Corp. (Nasdaq: BCTX) offers investors the potential for significant upside in the months ahead.

Key Reason #6: BriaCell Therapeutics Corp. is led by an expert drug development and financial team.

One of the most important keys to success when evaluating the potential for any biotech investment is the leadership team running the company.

Simply put, if the leadership team lacks experience in drug development…the chances for success are not great.

In the case of BriaCell Therapeutics Corp. (Nasdaq: BCTX), it’s important to note that the company’s clinical strategy team has been involved in 19 drug approvals.

The company’s President and CEO, Dr. William Williams is widely recognized as one of the foremost experts in drug development, with 11 successful new drug applications and approvals with the FDA and other regulatory agencies.

William V. Williams, MD, FACP – President and Chief Executive Officer

Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams has served as BriaCell’s President & CEO since Nov 2016.

Giuseppe Del Priore, MD, MPH – Chief Medical Officer

Dr. Del Priore is a seasoned healthcare executive with over 25 years of experience in research, drug development, and clinical trials management. Dr. Del Priore’s prior work experience includes serving as a biotech Chief Medical Officer, a National Director at the Cancer Treatment Centers of America (CTCA), plus faculty at Indiana University School of Medicine, Weill Cornell Medicine, and New York University School of Medicine. He has been involved in 8 drug or device approvals.

Miguel A. Lopez-Lago, PhD – Chief Scientific Officer

Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC). Specifically, he has investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis.

————————————————————————————————————————

Investor’s Summary:

BriaCell Therapeutics Corp. (Nasdaq: BCTX) is a clinical stage immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.

The company’s patented immunotherapy treatments have shown extraordinary potential, making it one of the more attractive high-upside biotech stocks for investors to consider in 2023.

[1] https://www.wsj.com/articles/the-biotech-takeout-menu-gets-pricier-11670477036

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Biotech-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for BriaCell Therapeutics Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BriaCell Therapeutics Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BriaCell Therapeutics Corp. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of BriaCell Therapeutics Corp. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by BriaCell Therapeutics Corp.; this is a paid advertisement, we currently own shares of BriaCell Therapeutics Corp. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) Has Put Out Historically Incredible Numbers in its Latest GOBLET Study Results, including a near TRIPLING of Objective Response (ORR) Rate, and a Statistically Unheard of Complete Response (CR) Rate—LEADING TO THE FDA GRANTING FAST TRACK DESIGNATION FOR PELAREOREP.

EDITOR’S NOTE* With Wall Street analyst coverage giving ONCY a price target of $15.00, these rock bottom prices you are currently seeing probably won’t last long – An earlier publication of this report saw a potential increase of 900% from its previous levels, prior to the beginning of what we believe will be a series of catalyst events on the horizon. NOW they’ve already begun with the FDA’s Fast Track Designation for pelareorep with pancreatic cancer. In the first day of trading after the Fast Track approval announcement, shares rose by 25%, showing that time is running out to get early positioning, so get positioned now! Take a look here: https://www.nasdaq.com/market-activity/stocks/oncy/analyst-research

We are getting closer and closer to downgrading pancreatic cancer from its reign as the highest mortality rate of all major cancers.[1]

Recently in the largest study of its kind (more than 10 million people),[2] researchers at the University of Surrey and the University of Oxford investigated known signs of pancreatic cancer[3] and discovered that it could potentially be diagnosed up to three years earlier—potentially increasing the chance of survival, and even making the disease curable if caught early enough.[4]

Now on top of this there’s even more promise coming from a potential therapy that’s delivered interim results from a Phase 1/2 study showing a 69% Objective Response Rate (ORR) in Pancreatic Cancer[5]—remarkably nearly triple the average ORR seen in historical control trials of another combination, which were only ~25%.[6]

As well, this new therapy achieved a Complete Response (CR), which in pancreatic cancer is almost UNHEARD OF. In a large historical control trial, there was a single CR in 861 patients, whereas this new therapy achieved a CR in just 13 patients—marking a significant potential 65x improvement over historical results!

The biotech company that developed this new therapy is Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), with their proprietary flagship asset pelareorep, which recently received FDA Fast Track designation which could propel the company into near-term cashflow.

Longer-term trends in pancreatic cancer reported by NIH/National Cancer Institute in the 2022 Cancer report, included the greatest incidence rate increase in men was seen in pancreatic cancer, and had increased by 1.1% per year.[7]

Even though pancreatic cancer accounts for only 3% of new cancer diagnoses, it accounts for 8% of cancer deaths, and is the fourth leading cause of cancer deaths in the USA for both men and women.[8]

However, there’s HOPE…

Within the NIH/National Cancer Institute’s report it also described pancreatic cancer’s survival improvements, with pancreatic neuroendocrine tumors increased from 65.9% to 84.2% between 2001 and 2017, and for people diagnosed with pancreatic adenocarcinomas it increased from 24.0% to 36.7%. Five-year relative survival also increased between 2001 and 2013, from 43.4% to 65.2% for people with pancreatic neuroendocrine tumors, and from 4.4% to 6.6% for people with pancreatic adenocarcinoma.

While all these signs of optimism are coming together, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is fully funded for a projected runway of key milestones to the end of 2023—including other forms of cancer.

All of these potential catalysts on the horizon have caused analyst firms—4 of 5 currently cited by NASDAQ—to make a STRONG BUY recommendation for Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), while they gave ONCY price targets that average $7.49 and run up to a high estimate of $15 per share, while Yahoo Finance is highlighting a 1-year target of $7.97, marking as high as a potential 594% increase over its current trading price of $2.16*.

(* – as of December 1, 2022)

As of November 28, 2022, the company has 5 firms with analysts giving ONCY coverage:[9]

• Cannaccord Genuity
• C. Wainwright
• Leede Jones Gable Inc.
• Maxim Group
• RBC Capital Markets

Now let’s break down the numerous reasons why we see Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) as THE BEST WAY to invest in the challenging world of biotech in the fight against cancer, with a company that appears statistically positioned to make a huge impact on the industry.

8 Reasons to Invest in Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) as a Cancer Battle Game Changer with PELAREOREP

 1   Pelareorep’s Big League Partnerships and Combos: Pelareorep’s potential has drawn a partnership with Adlai Nortye, co-development with Pfizer and Merck KGaA, as well as collaborations with SOLTI and Roche, as well as combinations in development with Merck & Co., Bristol-Myers Squibb, and Incyte.

 2   Near TRIPLING of Objective Response Rate (ORR): Compared to historical control trials by Dr. Von Hoff titled Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine yielded only about 25% ORR, while Oncolytics Biotech’s flagship pelareorep’s ORR was reported at 69% in the pancreatic cancer cohort with patients achieving a complete or partial response.[10]

 3  Achieved a Confirmed COMPLETE Response (CR): Also in the most recent results, pelareorep achieved a confirmed CR, which is almost unheard of, given that pelareorep achieved this with one of thirteen evaluable patients, while historical control trials only achieved one CR from a total of 861 patients—that’s a 7.7% rate vs a 0.12% rate, or a +6,500% (or 65x) improvement over the previous industry benchmark so far.

 4  Fast Track Designation GRANTED: On December 1, 2022, Oncolytics Biotech announced that the FDA granted Fast Track Designation to pelareorep for use in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC).

5  Synergy with Immune Checkpoint Inhibitors (ICIs): The ICI market is expected to exceed $55B by 2025[11], despite as few as 1 in 5 patients responding to ICI therapy[12]. Pelareorep has clinically demonstrated its ability to synergize with these ICIs, perhaps enhancing their effectiveness.

6  More Important Data to Come: Not only did Oncolytics Biotech present incredible data from its GOBLET study that led to its Fast Track designation, but there is also an upcoming catalyst expected in the first half of 2023 from its Phase 2 pelareorep-ICI combo trial in HR+/HER2- breast cancer to facilitate the asset’s advancement to a registrational study.

7  Strong Leadership Team: Proven Management Team and Board of Directors that combines over 150 years of experience in drug development and the biopharmaceutical industry, including a World Congress Pharma Executive of the Year award winner Chair of the Board.

8  Fully-Financed Through 2023 : As of September 30, 2022, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) has $32.4 million in cash and cash equivalents, which provides projected runway through key milestones to the end of 2023.

Pelareorep is an immunotherapeutic agent that generates an anti-tumor immune response, by training anti-cancer cells, while reversing immunosuppressive TMEs.

BREAST AND PANC: TWO LEGIT PATHS TO APPROVAL

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) has been clear in its objectives to target important segments, beginning with Breast Cancer, which is projected to reach US$55.27 billion by 2027, growing at a CAGR of 13.1% along the way.[13]

But don’t discount the potential for pelareorep’s approval to treat pancreatic cancer BEFORE it gets to that stage with breast cancer.

Why?

Because pancreatic cancer is a much deadlier cancer with a much faster progression.

Currently with an 89% mortality rate within the first 5 years,[14] and a 99% mortality rate within five years for Stage IV pancreatic cancer, [15] diagnoses of this deadly form of cancer is a nearly automatic death sentence. Once pancreatic cancer has spread to other organs, surrounding lymph nodes, or other parts of the body, the average life expectancy is just 3-6 months.[16] For patients who are diagnosed before the tumor grows much or spreads, the average pancreatic cancer survival time is 3 to 3.5 years.[17]

In comparison, breast cancer diagnoses carry with them an average 5-year survival rate of 90% across all SEER stages.[18]

This means that it’s theoretically much easier to quantify efficacy and an improvement of survival in pancreatic cancer, as data collection is in a much, much smaller window.

For every month a patient outlives the average life expectancy in the pancreatic cancer cohort, the more quantifiable the potential impact a therapy’s use can be.

Which brings us to ONCY’s GOBLET study.

NOW FOR THE NEXT BIG CATALYST IN THE MAKING

Prior to the GOBLET study, the control benchmarks for success in pancreatic cancer came in the 2013 reference in the New England Journal of Medicine by Dr. Von Hoff, titled Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.[19]

Why this study?

Because it fulfills the role of a historical control trial involving gemcitabine (gemzar) (Eli Lilly) plus nab-paclitaxel (Bristol-Myers Squibb).

How were the 2013 study’s results?

• The median overall survival (OS) was 8.5 months for the combo vs 6.7 months for gemcitabine alone
• The survival rate was 35% in the combo group vs 22% in the gemcitabine group alone at 1 year
  • 9% vs 4% at 2 years
• The median progression-free survival (PFS) was 5.5 months in the combo vs 3.7 months in the gemcitabine only group.
• The response rate was 23% vs 7%
• 1 in 861 (0.12%) patients achieved a Complete Response (CR)

Those results were good enough to see the FDA approve nab-paclitaxel for use in combination with gemcitabine to treat patients with metastatic pancreatic cancer in September of 2013. [20]

To recap, before it was approved, nab-paclitaxel:

• Increased mean overall survival (OS) duration by 26.8%
• Increased median progression free survival (PFS) duration by 48.6%
• Increased 1-year survival rate by 59%
• Increased 2-year survival rate by 125%
• Increased response rate by 228.5%

Now, the GOBLET study is evaluating pelareorep in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab and gemcitabine+nab-paclitaxel.

In late June, 2022, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) announced it had achieved success criteria for efficacy in the study’s pancreatic cancer cohort.[21]

NOW… we have the updated results from the phase 1/2 GOBLET study’s first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.

And they… were… FANTASTIC!

• 1 in 13 (7.7%) evaluable patients achieved a confirmed Complete Response (CR)
• 8 of 13 (61.5%) evaluable patients achieved a PR
• 2 of 13 (15.4%) evaluable patients achieved stable disease (SD)
• 9 of 13 (69.2%) evaluable patients achieved a response
• The observed ORR of 69% is substantially higher than the average ORR of ~25% reported in historical control trials of gemcitabine and nab-paclitaxel in pancreatic cancer[22]^{,[23],[24],[25]}
• GOBLET’s PDAC cohort exceeded the protocol-specified success criterion for Stage 1 of ≥ 3/12 objective responses
• The studied treatment combination has been well tolerated, with no safety concerns identified to date

A copy of the poster is available on the Posters & Publications page of Oncolytics’ website (LINK).

IMPORTANT UPDATE:

On December 1, 2022, Oncolytics Biotech proudly announced the FDA granted Fast Track Designation to pelareorep in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC).

“Receiving this Fast Track designation is an important accomplishment that speaks to the impressive response rate and the durability of the response in our PDAC study, and it also reflects the pressing need to improve upon the standard of care in this indication. With our core programs in breast and pancreatic cancer both nearing pivotal trials, and eligible for the Fast Track program’s numerous benefits, we believe we are at a crucial point in Oncolytics’ evolution and are excited for what’s ahead.”

– Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc.

FRIENDS IN HIGH PLACES

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) has established a successful partnership with Adlai Nortye in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. As per the relationship, there is an upfront and milestone payments of up to $86.6 million, with $65 million tied to potential development expansion.

Perhaps most notable are the ongoing studies Oncolytics is performing with Pfizer, Merck KGaA,  Incyte, and Roche. These involve checkpoint inhibitors, targeting metastatic breast cancer, early-stage breast cancer, triple-negative breast cancer, pancreatic cancer, colorectal cancer, and anal cancer.

BONUS CAR-T PROGRAM

 When Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) sought out the perfect combination for its flagship pelareorep’s immunotherapy capabilities, it became more and more obvious that the company was destined to enter the CAR-T therapy field, which has been dubbed a breakthrough treatment for patients with certain types of blood cancers, such as lymphoma and leukemia.

In 2020, treatment using CAR T-Cells led to complete remissions in 70% of patients[26] with anti-CD19-resistant acute B-cell leukemia.

It’s the perfect complement.

 Pelareorep is a naturally derived, non-genetically engineered oncolytic virus that can be delivered intravenously and that preferentially infects cancer cells. This means that pelareorep attacks and kills cancer cells while leaving healthy cells intact. As the virus kills cancer cells, it alerts the body to the presence of these cells and activates the immune system against the tumor. Despite being a virus, pelareorep is not known to cause any disease has been shown to be safe in over one thousand patients.

 CAR T cells, meanwhile, are created by drawing blood from a patient’s own body, separating the T-cells (which help produce an immune response and kill infected cells ), and genetically engineering them to produce receptors (chimeric antigen receptors, or CARs) on their surfaces.

 It is thought that pelareorep will enhance the effect of CAR T-cell therapy because the virus alerts the immune system to the presence of cancer cells, which can be good at hiding from the immune system. Treating them with pelareorep exposes them, and signals CAR T-cells to mount an assault on the cancer.

 For an extremely in-depth overview on what CAR T is and how it works, please watch this video located here:

THE BRAINTRUST BEHIND ONCOLYTICS BIOTECH

In order to take a proprietary biotech asset such as pelareorep through the trials along the road to approval, the entire process requires good stewardship. Thankfully, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is in VERY capable hands, built upon experience among management and directors with several leaders in the sector such as Amgen, Bristol-Myers Squibb, GSK, Sanofi Pasteur, National Institutes of Health, Harvard Medical School, and Princeton University.

ONCY’s leadership team includes:

Co-Founder, Director, President & CEO – Matt Coffey, PhD, MBA

Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results from his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal.

Head of Clinical Development and Operations – Thomas Heineman, MD, PhD

Dr. Heineman completed his medical degree and doctorate in Virology at the University of Chicago. His drug development experience spans more than 25 years including 15 years in the biopharmaceutical industry. He has held senior roles at GSK, were he led the clinical development of Shingrix, and at several biotechnology companies where his focus has been oncology and immuno-oncology. Dr. Heineman has led clinical programs in multiple oncology indications including breast cancer, pancreatic cancer, B-cell lymphoma, glioblastoma and colorectal cancer.

Global Head of Business Development – Andrew de Guttadauro

de Guttadauro is +25-year biopharmaceutical commercialization and business development veteran, who’s held executive and senior-level positions at leading pharmaceutical and biotechnology companies, including as VP of Corporate Development at Vical supporting the execution of distribution agreements for Allovectin^®, and a variety of positions at Amgen where he contributed to the success of Enbrel^®, Aranesp^®, and Epogen^® before joining MedImmune to lead marketing efforts for the FluMist^® inhaled influenza vaccine. He also served as Director of Strategy at Biogen Idec.

Chair of the Board – Wayne Pisano, MBA

Pisano was recognized as Pharma Executive of the Year by the World Vaccine Congress in 2010. He served as the President and CEO of VaxInnate, and has been a Board Member of Immunovaccine since 2011. He is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He’s credited with driving Sanofi Pasteur’s leadership within the worldwide influenza market and capturing 50% of global sales.

The remaining leadership roles, Board of Directors, and Scientific Advisory Board consist of highly qualified members, with senior level experience with such companies and institutions as: Ernst & Young LLP, Nabisco, Hospital for Sick Children, Aptose Biosciences, Achillion Pharmaceuticals, National Cancer Institute-Frederick Cancer Research and Development Center, GPC Biotech, Harvard Medical School, Princeton University,  Massachusetts General Hospital, EMD Serono, Breast International Group (BIG), SOLTI – Breast Cancer Research Group, Amgen & BMS IO Network and more.

Director – Deborah M. Brown, B.Sc., M.B.A.

Brown is currently a Managing Partner at Accelera Canada, a specialty consultancy firm that assists emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company’s U.S. operations, and President and Managing Director of the company’s Canadian operations. In 2012, Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA.

Director – Bernd R. Seizinger, MD, PhD

Dr. Seizinger currently serves as chairman/board member in a number of public and private biotech companies in the U.S., Europe and Canada, including: Vaccibody, Oxford BioTherapeutics, Aprea, CryptoMedix, and BioInvent. Previously he was President & CEO of public oncology company GPC Biotech; VP Oncology Drug Discovery and – in parallel – VP Corporate and Academic Alliances at Bristol-Myers Squibb; and Executive VP and CSO, Genome Therapeutics. Prior to his corporate appointments, he held Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.

RECAP: 8 IMPORTANT POINTS for Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)

1  Big League Partnerships and Combos

2  Near TRIPLING of ORR

3  Confirmed CR

4  Fast Track Designation GRANTED

5  Synergy with ICIs

6  More Important Data to Come

7 Strong Leadership Team

8 Fully-Financed Through 2023

BEFORE YOU GO

Now that you’ve read this far, the case has been made strong enough for you to get into action.

With what we believe are catalysts events coming in the very near future, and with the data we’ve already seen, we believe THIS IS THE PERFECT TIME for smart investors to seriously follow the ongoing ONCOLYTICS BIOTECH INC. (NASDAQ:ONCY) (TSX:ONC) story.

So, do your own due diligence, and don’t forget to click here to sign up for email alerts to make sure you don’t miss out on any of ONCY’s news and milestones.

USA News Group
Editorial Staff

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

[1] https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts/#:~:text=Pancreatic%20cancer%20has%20the%20highest,States%20after%20lung%20and%20colon.

[2] https://theconversation.com/pancreatic-cancer-could-be-diagnosed-up-to-three-years-earlier-new-study-192129

[3] https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0275369

[4] https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis

[5] https://ir.oncolyticsbiotech.com/press-releases/detail/586/oncolytics-biotech-presents-updated-clinical-data-at-sitc

[6] https://www.nejm.org/doi/full/10.1056/nejmoa1304369

[7] https://www.sciencedaily.com/releases/2022/10/221027170415.htm

[8] https://www.sciencedaily.com/releases/2022/10/221027170415.htm

[9] https://ir.oncolyticsbiotech.com/analyst-coverage

[10] https://ir.oncolyticsbiotech.com/press-releases/detail/586/oncolytics-biotech-presents-updated-clinical-data-at-sitc

[11] Cowen and Company, LLC, “Therapeutic Categories Outlook,” February 2021;

[12] JAMA Netw Open. 2019 May; 2(5): e192535

[13] https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163

[14] https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/

[15] https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis

[16] https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts/

[17] https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis

[18] https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

[19] https://www.nejm.org/doi/full/10.1056/nejmoa1304369

[20] https://www.cancer.gov/types/pancreatic/research/nab-paclitaxel-gemcitabine#:~:text=In%20September%202013%2C%20the%20U.S.,results%20of%20the%20MPACT%20trial

[21] https://ir.oncolyticsbiotech.com/press-releases/detail/578/oncolytics-biotech-achieves-success-criteria-for-efficacy

[22] Von Hoff D et al. N Engl J Med 2013; 369:1691-1703 DOI: 10.1056/NEJMoa1304369

[23] O’Reilly et al. Eur J Cancer. 2020 June; 132: 112–121. DOI:10.1016/j.ejca.2020.03.005

[24] Karasic et al. JAMA Oncol. 2019 Jul 1; 5(7):993-998. DOI: 10.1001/jamaoncol.2019.0684

[25] Tempero et al. Ann Oncol. 2021 May; 32(5):600-608. DOI: 10.1016/j.annonc.2021.01.070

[26] https://ascopubs.org/doi/full/10.1200/JCO.19.03279